As of 2024-12-14, the EV/EBITDA ratio of Fusion Antibodies PLC (FAB.L) is -2.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FAB.L's latest enterprise value is 5.21 mil GBP. FAB.L's TTM EBITDA according to its financial statements is -2.07 mil GBP. Dividing these 2 quantities gives us the above FAB.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 25.4x | 16.8x |
| Forward P/E multiples | 8.6x - 12.7x | 9.2x |
| Fair Price | (16.84) - (25.52) | (26.01) |
| Upside | -361.2% - -495.6% | -503.3% |
| Date | EV/EBITDA |
| 2024-11-20 | -1.47 |
| 2024-11-19 | -1.43 |
| 2024-11-18 | -1.64 |
| 2024-11-15 | -1.49 |
| 2024-11-14 | -1.42 |
| 2024-11-13 | -1.35 |
| 2024-11-12 | -1.37 |
| 2024-11-11 | -1.42 |
| 2024-11-08 | -1.42 |
| 2024-11-07 | -1.40 |
| 2024-11-06 | -1.45 |
| 2024-11-05 | -1.47 |
| 2024-11-04 | -1.47 |
| 2024-11-01 | -1.45 |
| 2024-10-31 | -1.45 |
| 2024-10-30 | -1.45 |
| 2024-10-29 | -1.49 |
| 2024-10-28 | -1.47 |
| 2024-10-25 | -1.40 |
| 2024-10-24 | -1.35 |
| 2024-10-23 | -1.35 |
| 2024-10-22 | -1.35 |
| 2024-10-21 | -1.37 |
| 2024-10-18 | -1.45 |
| 2024-10-17 | -1.49 |
| 2024-10-16 | -1.78 |
| 2024-10-15 | -1.42 |
| 2024-10-14 | -1.42 |
| 2024-10-11 | -1.47 |
| 2024-10-10 | -1.47 |
| 2024-10-09 | -1.47 |
| 2024-10-08 | -1.49 |
| 2024-10-07 | -1.37 |
| 2024-10-04 | -1.35 |
| 2024-10-03 | -1.45 |
| 2024-10-02 | -1.33 |
| 2024-10-01 | -1.42 |
| 2024-09-30 | -1.45 |
| 2024-09-27 | -1.52 |
| 2024-09-26 | -1.68 |
| 2024-09-25 | -1.56 |
| 2024-09-24 | -1.37 |
| 2024-09-23 | -0.99 |
| 2024-09-20 | -0.99 |
| 2024-09-19 | -0.99 |
| 2024-09-18 | -0.99 |
| 2024-09-17 | -1.02 |
| 2024-09-16 | -1.16 |
| 2024-09-13 | -1.11 |
| 2024-09-12 | -1.06 |